Companies › Korea United Pharm.
4 active drug programs in 4 registered trials: 4 Phase 1; Cardiovascular.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| UIC202502 | – | Phase 1 | Dyslipidemia | – |
| UIC202505 | – | Phase 1 | Dyslipidemia | – |
| UIC202601 | – | Phase 1 | Hypertension | – |
| UIC202602 | – | Phase 1 | Hypertension | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07162441 | UIC202502 | Phase 1 | Dyslipidemia | Cardiovascular | Sep 2025 |
| NCT07162441 | UIC202505 | Phase 1 | Dyslipidemia | Cardiovascular | Sep 2025 |
| NCT07682948 | UIC202601 | Phase 1 | Hypertension | Cardiovascular | Sep 2026 |
| NCT07682948 | UIC202602 | Phase 1 | Hypertension | Cardiovascular | Sep 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.